A new study has identified a major reason why many promising cancer drugs fail in late-stage clinical trials after showing initial success. Researchers discovered that the preclinical models used to test these drugs, particularly patient-derived xenografts (PDX) in mice, often lack a complete human immune system. This critical gap means the models cannot accurately predict …
A new study has identified a major reason why many promising cancer drugs fail in late-stage clinical trials after showing initial success. Researchers discovered that the preclinical models used to test these drugs, particularly patient-derived xenografts (PDX) in mice, often lack a complete human immune system. This critical gap means the models cannot accurately predict how a human immune response will interact with the therapy, leading to unexpected failures when the drugs move to human trials. The findings highlight the need for more sophisticated testing models that incorporate human immune components to better forecast real-world efficacy and improve the drug development pipeline. Read the full article at https://www.sciencedaily.com/releases/2026/04/260409101055.htm
Join the Club
Like this story? You’ll love our Bi-Weekly Newsletter
